DNA

Company Statement on FDA Advisory Committee Meeting  

MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug…

1 year ago

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology…

1 year ago

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…

1 year ago

New Research Reveals More Hospitals and Health Systems are Investing in Artificial Intelligence (AI) for Improving Revenue Cycle Management (RCM)

Survey results indicate that most organizations are planning to invest in AI within the next 1-3 years and are expecting AI…

1 year ago

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and…

1 year ago

University of California Transforms Life Science Research Procurement with Labviva

University of California selects AI purchasing platform to accelerate scientific and research procurement for 10 campusesOAKLAND, Calif., Sept. 12, 2024…

1 year ago

Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss

Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x higher.Noom stands…

1 year ago

CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim

New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart…

1 year ago

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo…

1 year ago

Peer-Reviewed Study Validates Reliability and Reproducibility of Esopredict, Previse’s Prognostic Assay for Patients with Barrett’s Esophagus

BALTIMORE, Sept. 11, 2024 /PRNewswire/ -- Previse, a gastrointestinal health company, announced the publication of a study in Diagnostics highlighting the…

1 year ago